Remarkably, 341G2 hIgG2 was found to exhibit four times higher potency than CP870,893 which remains the most agonistic anti-CD40 mAb to be tested clinically to date, capable of delivering some objective partial responses in cancer patients (Vonderheide et al., 2007). Here, CD40 is linked to cancer.